#Mesenchymal Epithelial Transition Factor market | Explore Tumblr posts and blogs

delveinsight12 · 1 month ago

Text

MET Kinase Inhibitor Market: Size, Target Population, Competitive Landscape, and Forecast to 2034

The MET kinase inhibitor market represents a significant and rapidly advancing segment of cancer therapeutics, particularly in addressing malignancies driven by MET (mesenchymal-epithelial transition factor) signaling dysregulation. These inhibitors target the MET pathway, which is implicated in tumor growth, metastasis, and treatment resistance in various cancers. Here, we delve into the market dynamics, including its size, target population, competitive environment, and future outlook to 2034.

MET Kinase Inhibitor Market Size and Growth Drivers

The MET kinase inhibitor market is forecasted to experience substantial growth through 2034, driven by advancements in oncology research and the increasing prevalence of MET-driven cancers. MET pathway dysregulation is common in cancers like non-small cell lung cancer (NSCLC), gastric cancer, and papillary renal cell carcinoma, creating significant demand for targeted therapies.

The market is buoyed by:

- Expanding therapeutic applications: Beyond cancer, MET inhibitors are being explored for fibrotic and inflammatory diseases, which could broaden their market scope.

- Rising investments in oncology: Governments and private entities are boosting funding in cancer research, accelerating drug development and commercialization.

- Improved diagnostic capabilities: Advances in precision medicine enable better identification of MET-amplified or overexpressed tumors, facilitating targeted treatment.

North America and Europe are leading markets due to robust healthcare infrastructure and innovation hubs. Meanwhile, the Asia-Pacific region is poised for rapid growth, propelled by rising healthcare spending and increased cancer awareness.

Request for a sample page report @ https://www.delveinsight.com/sample-request/met-kinase-inhibitor-market-forecast

MET Kinase Inhibitor Target Population

The primary target population for MET kinase inhibitors includes patients with cancers harboring MET alterations:

- Non-Small Cell Lung Cancer (NSCLC): MET exon 14 skipping mutations and MET amplifications are significant targets in this subset of lung cancer patients.

- Gastric Cancer: MET overexpression is a critical factor in the pathogenesis of gastric and gastroesophageal cancers.

- Renal Cell Carcinoma: MET alterations drive tumor progression in some forms of kidney cancer.

Emerging evidence suggests potential applications in other cancers, including colorectal and breast cancer, expanding the addressable patient pool.

MET Kinase Inhibitor Competitive Landscape

The MET kinase inhibitor market is highly competitive, with both established pharmaceutical giants and innovative biotech companies actively participating. The competition is characterized by diverse therapeutic approaches, including small molecules and antibody-based inhibitors.

MET Kinase Inhibitor Key Players and Therapies

1. Novartis: The company's MET inhibitor, Capmatinib (Tabrecta), is approved for MET exon 14 skipping-mutated NSCLC, setting a benchmark for others in the field.

2. Merck KGaA: Tepotinib (Tepmetko) has shown significant efficacy in treating MET-altered NSCLC, particularly in Asian markets.

3. Eli Lilly: Lilly is actively exploring the potential of MET inhibitors as part of its oncology portfolio.

4. Emerging Biotechs: Several smaller firms are developing novel MET inhibitors, including bispecific antibodies that simultaneously target MET and other pathways to overcome resistance mechanisms.

MET Kinase Inhibitor Pipeline Developments

Over 20 candidates are in various stages of development, reflecting a rich pipeline. Research is focused on improving specificity, reducing toxicity, and exploring combination therapies with immune checkpoint inhibitors and other agents.

MET Kinase Inhibitor Technological Innovations

Innovation is pivotal to the MET inhibitor market. Key advancements include:

- Combination Therapy: Co-targeting MET and other pathways, such as EGFR or ALK, to enhance efficacy and overcome resistance.

- Biomarker-Driven Approaches: Precision diagnostics are integral to identifying suitable patients, ensuring higher therapeutic success.

- Optimized Delivery Systems: Improving oral bioavailability and reducing side effects are priorities in new formulations.

Download sample report @ https://www.delveinsight.com/sample-request/met-kinase-inhibitor-market-forecast

MET Kinase Inhibitor Market Challenges

Despite its promising trajectory, the MET kinase inhibitor market faces challenges:

1. Resistance Development: Tumors often develop resistance to MET inhibitors, necessitating new-generation therapies.

2. High Costs: Expensive R&D processes and drug pricing limit accessibility, particularly in emerging markets.

3. Regulatory Hurdles: The stringent regulatory environment requires extensive clinical data for approval, prolonging time-to-market.

These challenges are being addressed through collaborative R&D, cost-sharing models, and regulatory streamlining.

MET Kinase Inhibitor Forecast to 2034

The MET kinase inhibitor market is projected to achieve multi-billion-dollar revenues by 2034, with a robust CAGR. Growth will be driven by:

- Expanded Indications: Beyond oncology, research into MET inhibitors for fibrosis and inflammatory diseases could open new markets.

- Global Access: Initiatives to improve drug affordability and access in low- and middle-income countries will play a key role in market expansion.

- Technological Advancements: Continued innovation in drug delivery and biomarker-driven treatments will enhance adoption.

North America and Europe will maintain leadership in market share, while Asia-Pacific emerges as a key growth region due to rising healthcare infrastructure and patient awareness.

The MET kinase inhibitor market represents a dynamic and transformative segment in precision oncology. With ongoing advancements in diagnostics, therapeutic efficacy, and broader clinical applications, MET inhibitors hold immense potential to redefine cancer treatment paradigms. Stakeholders—including pharmaceutical companies, healthcare providers, and policymakers—must navigate challenges while seizing opportunities to capitalize on this promising market.

For a comprehensive analysis, including detailed market forecasts and emerging trends, refer to the [DelveInsight MET Kinase Inhibitor Market Report](https://www.delveinsight.com/report-store/met-kinase-inhibitor-market-forecast).

0 notes

prnlive · 2 years ago

Text

Gary Null’s Show Notes 01 31 23 P

If you listen to Gary’s show, you know that he begins with the latest findings in natural approaches to health and nutrition. Starting this week, we will make some of those findings available each weekday to subscribers to the Gary Null Newsletter.

Research Confirms Ayurvedic Spice Good for Prostate

Gut Bacteria Could be Key to Preventing Alzheimer's

‘Unprecedented in its potential impact’: Could new anti-cancer study re-ignite the kava market?

The Case for Eating Pulses

People with cluster headaches more likely to have other illnesses, study finds

Vitamin D improves symptoms of toxic erythema during chemotherap

Research Confirms Ayurvedic Spice Good For Prostate

Chieti-Pescara University (Italy), January 13, 2023

Biomedical researchers from Italy's Chieti-Pescara University have confirmed what recent laboratory research has found: That the Ayurvedic herb turmeric (Curcuma longa) increases quality of life and reduces symptoms of non-cancerous enlarged prostate also known as benign prostatic hyperplasia.

The ancient Ayurvedic herbal remedy joins the list of several other nutraceuticals that have now been scientifically confirmed to reduce enlarged prostate

For six months the researchers gave 33 patients diagnosed with benign prostatic hyperplasia with a turmeric extract of curcumin in addition to standard conventional BPH treatment (no drugs). A control group of 28 BPH patients matched for age and severity received only the conventional BPH treatment (again, without drugs).

While both groups experienced improvement in most symptoms, the curcumin-treated group experienced greater improvement. The curcumin-treated group also experienced higher quality-of-life scores than did the conventional treatment group.

The researchers concluded: "In patients with BPH, the addition of curcumin to the standard treatment contributed to the reduction of signs and symptoms of the disease without causing any significant additional side effect. This pilot experience suggests a potential novel clinical application of curcumin..."

This isn't the first study that has indicated curcumin's ability to treat enlarge prostate. A study from the Seoul National University College of Medicine found that curcumin inhibited hypoxia-inducible factor 1alpha (HIF-1alpha) in both animal and human prostrate cell tests. This inhibition resulted in a reduction of inflammation – hyperplasia – among the prostate cells. This in turn mediated epithelial-mesenchymal transition (EMT) markers, directly related to inflammation.

Gut Bacteria Could Be the Key to Preventing Alzheimer’s

Washington University School of Medicine, January 20, 2023 The key to preventing and treating Alzheimer’s disease may lie in our gut bacteria as well as our brains. A new study suggests that the bacteria inhabiting the gut affect immune responses in the brains of mice, leading to changes in the rate of neurodegeneration. As evidence mounts that a healthy microbiome benefits many aspects of our health, this discovery may open new avenues for treating Alzheimer’s in humans. Where you live, what you eat, and your lifestyle all have an effect on the gut microbiome, and populations of microbes in it change throughout a person’s lifetime. People with Alzheimer’s disease have much lower microbial diversity in their gut than those who are healthy, and several studies point to the microbiome driving the development of neurodegenerative disorders, such as Alzheimer’s and Parkinson’s disease. In this new study from Washington University School of Medicine in St. Louis, mice genetically modified to develop Alzheimer’s were divided into two groups. One was raised in sterile conditions from birth and did not develop any gut microbiome, the other received antibiotics to permanently change their gut flora. After 40 weeks, the brains of mice kept in sterile conditions showed much less neurodegeneration than those with typical mice microbiomes. The outcome in mice in the antibiotic group was less clear cut: male mice showed less brain damage than female mice. The researchers also found that three short-chain fatty acids produced by certain types of gut bacteria were associated with neurodegeneration. This suggests that modifying the gut microbiome with antibiotics, probiotics, specialized diets, or other means may offer a new approach to preventing and treating neurodegenerative diseases, such as Alzheimer’s, in people.

‘Unprecedented in its potential impact’: Could new anti-cancer study re-ignite the kava market?

University of Minnesota, January 10, 2023

A patent-pending blend of compounds from kava with none of the potentially adverse liver effects may see the much-maligned herb re-emerge in the dietary supplement space, say researchers from the University of Minnesota.

Kava, aqueous extracts from the roots of Piper methysticum, is traditionally served as a beverage for South Pacific islanders. Epidemiologic evidence has also linked kava to a very low incidence of certain cancers in several South Pacific countries, proposed to be related to the presence of compounds called kavalactones. Organic extracts also have a long history of traditional use for anxiety.

However, kava has often made headlines for the wrong reasons, with reports of potential liver toxicity associated with various commercially available kava-containing dietary supplements being reported for over 10 years. As a result of this, many regulatory bodies around the world have restricted the product, or issued official recommendations to avoid use.

Researchers from the University of Minnesota have now identified the naturally occurring components of kava that appear responsible for all the cancer-preventative benefits. The team also found that daily consumption of the kava-derived product prevented the formation of 99% of tumors in a mouse model that is routinely used in predicting lung cancer behavior in humans.

Some mice developed no tumors at all, according to findings published in Cancer Prevention Research . DNA damage resulting from tobacco carcinogens was also significantly reduced by way of prevention.

In addition, by carefully selecting only the cancer-preventative compounds, the research team was also able to avoid liver damage.

“This research is truly unprecedented in its potential impact,” said Dr Kingston. “A 99% cancer prevention efficacy is unheard of with this very sensitive research model and paves the way for future clinical trials to assess human applications.

““Kava could be a good or bad product depending on how you prepare it,” said Chengguo (Chris) Xing, PhD, an associate professor of medicinal chemistry at the University of Minnesota College of Pharmacy, and co-author on the new paper.

“Recently supplements have suffered quite a bit of negative publicity — some of it deserved, some not — but the kava study from the University of Minnesota emphasizes what good science coupled with quality botanicals can produce."

The Case for Eating Pulses

University of Copenhagen, January 20, 2023

Pulses, which have two- to three-times the protein as cereals, could replace meat protein while being sustainable and climate friendly.

Pulses have a unique ability to capture nitrogen from the air and fix it to soil to create fertilizer, which benefits other plants as well. This makes the need for additional fertilizer negligible, as well as the crop’s greenhouse gas emissions.

In her studies, Katharina Henn aimed to get an overview of pulse consumption across Europe, and in doing so, identify the obstacles that challenge consumers.

People in Denmark have roughly average knowledge of pulses, they come in last place for quantity and variety of pulses eaten. Spain is at the top of the class when it comes to awareness, the variation of pulses used and total consumption. The country’s historic interaction with Middle Eastern culinary traditions could be the reason. Regardless, pulses are a natural part of Spain’s Mediterranean diet, notes Henn. In Germany, her own country, the traditions have been forgotten.

“There is a lot of interest in meat substitutes because the industry thinks that consumers need products which resemble familiar foods, like burger patties. But from a nutritional perspective, we don’t need these imitation products. In fact, our studies show that consumers would often prefer pulses just as they are,” says Henn

The studies also included a life cycle assessment for pulses which lays out their greenhouse gas footprints from production to consumption—start to finish.

Average greenhouse gas emissions (in CO2) for various pulses:

Dried beans: 11 kg CO2/kg protein

Canned beans: 23 kg CO2/kg protein

Beef: 499 kg CO2/kg protein

Lamb: 198.5 kg CO2/kg protein

Protein: 190 kg CO2/kg protein

Cheese: 108 kg CO2/kg protein

“Our global population has just reached 8 billion and we are amid a climate crisis. This calls for three things that pulses can deliver: Food production that can nourish a growing population; that can be climate friendly without significant greenhouse gas emissions; and do so in a future with more difficult growing conditions that includes drought, among other things,” says Henn.

People with cluster headaches more likely to have other illnesses, study finds

Karolinska University Hospital (Sweden), January 20, 2023

Cluster headaches are attacks of severe pain often felt on one side of the head and often around the eye.

The rare condition, affecting around 0.1% of the population, can be debilitating. People affected with cluster headaches can experience up to eight per day, with each one lasting anywhere between 15 and 180 minutes.

Cluster headaches are relatively short-lasting compared to migraine. Still, he describes the pain as “very severe (more so than any other pain reported)” and can also be accompanied by other “prominent features of eye-watering, redness, and nasal congestion.”

The cause of cluster headaches is not fully understood. Previous research suggests that the condition may be linked to abnormalities in the hypothalamus – the area of the brain which controls circadian rhythm.

New research at Karolinska University Hospital and Danderyd Hospital in Sweden suggests that people with cluster headaches are more likely to have other illnesses and have time off from work.

The study compared the works records and health data of 3,240 people diagnosed with cluster headaches to 16,200 people without cluster headaches.

Cluster headaches were associated with an increase in other diseases, including heart disease, mental disorders, and neurologic diseases. Indeed 92% of the people in the study with cluster headaches also had at least one other illness.

Interestingly, despite cluster headaches affecting men more than women, researchers found that 96% of the female participants in the study with cluster headaches had an additional illness compared to 90% of men.

Researchers found that during the study period, people with cluster headaches were almost twice as likely to take sick days as those without, 63 days compared to 34 days respectively.

Vitamin D found to improve symptoms of toxic erythema during chemotherapy

Northwestern University, January 19, 2023

High doses of vitamin D alleviated symptoms for patients with toxic erythema of chemotherapy (TEC) significantly faster than current treatments, according to a Northwestern Medicine study published in JAMA Dermatology.

TEC is a common side effect of chemotherapy in which patients develop severe redness, blistering and swelling, often affecting the hands, feet or areas on the body with skin folds.

Previous work from Northwestern Medicine investigators demonstrated that high doses of vitamin D improved erythema in patients with severe sunburn and chemotherapy-related skin injuries, suggesting that the same results might apply in the case of TEC.

"With toxic erythema of chemotherapy, the chemotherapy causes toxic injury to skin, somewhat similarly to how UV radiation may cause direct skin injury," said Cuong Nguyen, MD, assistant professor of Dermatology in the Divisions of Dermatopathology and Medical Dermatology, of Medicine in the Division of General Internal Medicine, and lead author of the study.

In the current study, Nguyen's team evaluated six patients between the ages of 36 and 38 years with TEC who received high doses of vitamin D at an academic medical center.

Four of the patients were diagnosed with acute myeloid leukemia and one with aplastic anemia, all of whom required chemotherapy before undergoing a stem cell transplant. One patient developed TEC after receiving chemotherapy for glioblastoma.

The onset of TEC occurred about one week after patients received chemotherapy treatment, who were then given varying dosages of vitamin D.

All patients experienced improvements in pain, itchiness or swelling after one day of treatment and improvement in redness within one to four days of treatment.

About Gary Null

An internationally renowned expert in the field of health and nutrition, Gary Null, Ph.D is the author of over 70 best-selling books on healthy living and the director of over 100 critically acclaimed full-feature documentary films on natural health, self-empowerment and the environment. He is the host of ‘The Progressive Commentary Hour” and “The Gary Null Show”, the country’s longest running nationally syndicated health radio talk show which can be heard daily on here on the Progressive Radio Network.

Throughout his career, Gary Null has made hundreds of radio and television broadcasts throughout the country as an environmentalist, consumer advocate, investigative reporter and nutrition educator. More than 28 different Gary Null television specials have appeared on PBS stations throughout the nation, inspiring and motivating millions of viewers. He originated and completed more than one hundred major investigations on health issues resulting in the use of material by 20/20 and 60 Minutes. Dr. Null started this network to provide his followers with a media outlet for health and advocacy. For more of Dr. Null’s Work visit the Gary Null’s Work Section or Blog.GaryNull.com In addition to the Progressive Radio Network, Dr. Null has a full line of all-natural home and healthcare products that can be purchased at his Online Store.

Find articles, videos, back radio broadcasts, books, and more at GaryNull.com.

https://garynull.com

Find Gary's vitamins and other supplements at Gary's Vitamin Closet.

https://www.garysvitamincloset.com

Hear Gary's radio show weekdays at noon Eastern Time on PRN.live

Disclaimer

While we have thoroughly researched the information we provide, and indicate its sources, information in this Gary Null Newsletter, and all Gary Null Newsletters, is for educational and informational purposes only, and is not intended to diagnose, treat, cure or prevent any disease or other condition. Consult your medical professional before choosing any treatment or course of action. Gary Null Newsletters are not liable for risks or issues associated with using or acting upon the information it provides.

Let us know what you would like to see in Gary's newsletter. Email us at [email protected]

If you are not subscribed, go to: https://garynull.substack.com to subscribe.

0 notes

sohamtmr · 2 years ago

Text

Kinase Inhibitors Market Is Projected To Expand At A Cagr Of 4% From 2019 To 2027

Kinase Inhibitors Market: Introduction

According to the report, the global kinase inhibitors market was valued at ~US$ 46.4 Bn in 2018 and is projected to expand at a CAGR of ~4% from 2019 to 2027. Kinase inhibitors are available in various types including non-receptor tyrosine kinase inhibitors, receptor tyrosine kinase inhibitors, multikinase inhibitors, serine/threonine kinase inhibitors, protein kinase C inhibitors, RHO kinase inhibitors, and others. Various applications of kinase inhibitors include oncology, inflammatory diseases, and others. Growth of the global kinase inhibitors market can be attributed to rise in awareness about kinase inhibitors and surge in product approvals and increase in incidence of cancer across globe.

North America dominated the global kinase inhibitors market in 2018 and the trend is anticipated to continue during the forecast period. Rise in awareness about new drugs for treatment and availability of all major companies in the region are anticipated to drive the market in North America. Asia Pacific is expected to be a highly lucrative market for kinase inhibitors, expanding at a higher CAGR during the forecast period.

Get Sample Copy of the Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=818

Increase in Incidence of Cancer, Rise in Awareness about Kinase Inhibitors, and Surge in Product Approvals to Drive Market

Cancer has a major impact on the society across the world. It is one of the leading causes of death across the globe and is more prevalent in developed and emerging markets. According to the American Cancer Society data, over 1.7 million new cancer cases are expected to be diagnosed in 2019 in the U.S. Awareness about cancer diagnosis and treatment is being spread across the globe. Governing bodies are also taking initiatives to provide access to health care to the public. Companies are taking initiatives to launch more products for the treatment. Intense drug discovery programs have led to the development of clinically effective kinase inhibitors. Since 2001, more than 10,000 patent applications for kinase inhibitors have been filed in the U.S. alone.

Non-receptor Tyrosine Kinase Inhibitors to Witness High Demand

Based on type, the global kinase inhibitors market has been divided into non-receptor tyrosine kinase inhibitors, receptor tyrosine kinase inhibitors, multikinase inhibitors, serine/threonine kinase inhibitors, protein kinase C Inhibitors, RHO kinase inhibitors, and others. Non-receptor tyrosine kinase inhibitors is further segmented into Bruton's tyrosine kinase (BTK) inhibitors, BCR-ABL, Janus kinase (JAK) inhibitor, mesenchymal epithelial transition growth factor (c-MET), spleen tyrosine kinase (SYK) inhibitors, and others. The receptor tyrosine kinase inhibitors segment is again divided into VEGFR, PDGFR, EGFR, ALK, HER2, and others.

The non-receptor tyrosine kinase inhibitors segment dominated the global kinase inhibitors market in 2018 and the trend is likely to continue during the forecast period. Rise in approvals of different types of non-receptor tyrosine kinase inhibitors fuels the segment growth. In November 2019, FDA approved Bruton's tyrosine kinase (BTK) inhibitor zanubrutinib (Brukinsa) for patients with relapsed and refractory mantle cell lymphoma.

Get Custom Research Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=818

Oncology to be Key Application Area

In terms of application, the global kinase inhibitors market has been segmented into oncology, inflammatory diseases, and others. Oncology is further divided into lung cancer, renal cell cancer, breast cancer, and others. The oncology segment dominated the global kinase inhibitors market in 2018 and is expected to grow with the highest CAGR in the forecast period. Large number of approved drugs along with rich product pipeline for cancer treatment is anticipated to fuel the growth of the segment in the near future. Based on data from clinicaltrials.gov last updated on January 2020, over 75 kinase inhibitor drugs are in various phases of clinical trials for the application of oncology.

Rise in Number of Hospital Pharmacies to Drive Market

Based on distribution channel, the global kinase inhibitors market has been segmented into hospital pharmacies, independent pharmacies, and online pharmacies. The hospital pharmacies segment dominated the global kinase inhibitors market in terms of revenue in 2018 and the trend is projected to continue during the forecast period. Increase in number of prescription-based kinase inhibitors being dispensed through independent pharmacies and rise in number of independent pharmacies in developing countries make these pharmacies a major channel of distribution.

North America to Dominate Global Market

Enquiry Before Buying @ https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=818

The kinase inhibitors market in Asia Pacific is likely to expand at a higher CAGR from 2019 to 2027. Significant growth of the kinase inhibitors market in the region can be attributed to high prevalence of cancers and increase in demand for its therapeutics.

About Us

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.

Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports.

For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update - https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ

Contact

Nikhil Sawlani Transparency Market Research Inc. CORPORATE HEADQUARTER DOWNTOWN, 1000 N. West Street, Suite 1200, Wilmington, Delaware 19801 USA

#healthcare #medicine

0 notes

healthcare-market · 4 years ago

Text

Kinase Inhibitors Market Key Insights, Profiling Companies and Growth Strategies

Kinase Inhibitors Market: Introduction

Request a PDF Brochure - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=818

Increase in Incidence of Cancer, Rise in Awareness about Kinase Inhibitors, and Surge in Product Approvals to Drive Market

Request a Sample of Kinase Inhibitors Market: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=818

Non-receptor Tyrosine Kinase Inhibitors to Witness High Demand

Request for Analysis of COVID19 Impact on Kinase Inhibitors Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=818

Oncology to be Key Application Area

Rise in Number of Hospital Pharmacies to Drive Market

North America to Dominate Global Market

Geographically, the global kinase inhibitors market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global kinase inhibitors market in 2018, followed by Europe. North America accounted for major share of the global kinase inhibitors market in 2018, owing to introduction of new drugs, and high prevalence of cases in countries such as the U.S. The kinase inhibitors market in Asia Pacific is likely to expand at a higher CAGR from 2019 to 2027. Significant growth of the kinase inhibitors market in the region can be attributed to high prevalence of cancers and increase in demand for its therapeutics.

Buy now Kinase Inhibitors Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=818&ltype=S

Competition Landscape

Novartis AG, Pfizer, Johnson & Johnson, AstraZeneca, and Bristol-Myers Squibb are the leading players in the global kinase inhibitors market that hold majority of the market share. The global kinase inhibitors Market is fragmented in terms of number of players. Key players in the global market include Novartis AG, Pfizer, Johnson & Johnson, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim International GmbH, Bayer AG, F. Hoffmann-La Roche Ltd, and Eisai Co., Ltd. New product development through robust R&D activities and merger & acquisitions are the key strategies adopted by these players to operate their business in the global kinase inhibitors market

More Trending Reports by Transparency Market Research:

https://www.prnewswire.com/news-releases/prevalence-of-chronic-diseases-that-need-surgical-processes-spurs-sales-in-surgical-drills-market-valuation-to-rise-at-cagr-of-4-7-during-20182026-tmr-301265120.html

https://www.prnewswire.com/news-releases/international-accreditations-for-hospitals-drive-prospects-of-medical-tourism-market-in-offering-quality-patient-care-revenues-to-rise-at-cagr-of-10-5-from-2019-to-2027-tmr-301269941.html

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of analysts, researchers, and consultants, uses proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

0 notes

pharmaphorumuk · 4 years ago

Text

J&J files lung cancer bispecific amivantamab for FDA approval

Johnson & Johnson has filed its bispecific antibody amivantamab to the FDA, hoping to muscle into the big market for drugs that are used to treat EGFR-positive non-small cell lung cancer (NSCLC).

J&J’s Janssen unit is seeking approval of the drug in a specific patient group – those with exon 20 insertion mutations whose disease has progressed despite first-line chemotherapy.

Janssen has ambitions to expand the use of the drug into the larger EGFR inhibitor market, which at the moment, is led by AstraZeneca’s fast-growing EGFR tyrosine kinase inhibitor (TKI) Tagrisso (osimertinib).

Amivantamab (formerly JNJ-6372) is a bispecific or double-headed antibody, combining an EGFR-binding domain at one end with one targeting mesenchymal epithelial transition (MET) factor, which is a common resistance mechanism that can reduce the activity of EGFR drugs.

That means it targets both the primary mutation in this form of NSCLC and the resistance mechanism at the same time, according to J&J, which has previously said it plans to expand use of the drug to “all EGFR-containing tumours”, challenging Tagrisso and other TKIs like AZ’s older Iressa (gefitinib) and Roche’s Tarceva (erlotinib).

Amivantamab is also the first drug to be filed specifically for patients with exon 20 mutations, who don’t tend to respond well to current therapies including EGFR inhibitors, and as a result picked up a breakthrough designation from the FDA for this use.

EGFR mutations are some of the most common mutations in NSCLC, and that has driven sales of Tagrisso – the standard of care for previously-untreated EGFR-positive NSCLC – to more than $3 billion last year.

The Exon 20-mutated population is fairly large in its own right, as these mutations are the third most prevalent primary EGFR mutation. That said, they often go undetected, so J&J will have to develop ways to identify suitable patients if amivantamab is to make headway in the market.

In the summer, the drugmaker signed partnered with Guardant Health to seek regulatory approval of a companion diagnostic for amivantamab that will be used to identify suitable patients.

Along with the marketing approval submission, J&J has also set up an expanded access programme, which would allow patients at need to use the drug while the FDA review is underway.

Patients with exon 20 insertion mutations have a median survival of less than 17 months, around half that of patients with other EGFR mutations.

Amivantamab has been filed for approval based on the phase 1 CHRYSALIS study which showed that the drug shrank tumours in 36% of all patients in the study, and 41% of those previously treated with chemo. The median durations of response were 10 months and seven months, respectively.

CHRYSALIS also included an arm that combined amivantamab with lazertinib, an experimental EGFR TKI that J&J licensed from South Korea’s Yuhan in 2018, which showed a 100% ORR with the combination in previously-untreated EGFR-mutant NSCLC.

That result prompted J&J to start a phase 3 trial comparing the duo to Tagrisso directly in treatment-naïve patients. Called MARIPOSA, it will compare Tagrisso to lazertinib alone as well as the combination.

Meanwhile, J&J is also exploring the use of amivantamab in patients who have failed TKI therapy and only have chemo as an option.

Both lazertinib and amivantamab – which was developed using technology from Danish biotech Genmab – have blockbuster sales potential, according to the company.

The post J&J files lung cancer bispecific amivantamab for FDA approval appeared first on .

from https://pharmaphorum.com/news/jj-files-lung-cancer-bispecific-amivantamab-for-fda-approval/

0 notes

kritikarehani · 4 years ago

Photo

Cellular-mesenchymal Epithelial Transition Factor (C-Met) Mutated Non-small Cell Lung Cancer (NSCLC) Market

C-Met mutated NSCLC Market

The total incident cases of C-Met mutated NSCLC in the 7MM was 16,658 in 2017. The C-Met accounted for approximately 4% of the total cases of NSCLC. In 2017, with 7,202 cases the United States had the highest number of C-Met mutated NSCLC cases among the 7MM, while Spain with 869 cases had the lowest registered cases.

The market size of C-Met mutated NSCLC in the 7MM was found to be USD 186 Million in 2017, which is expected to increase during the forecast period 2017-2030.

Increasing use of biomarker testing, increase in mutation specific trials activity, increasing incidence of C-Met mutated NSCLC are some of the key drivers for the C-Met NSCLC market.

The key companies in the C-Met mutated NSCLC market includes Novartis, Merck, Janssen Pharmaceutical, Eli Lilly and Company, AbbVie, Symphogen, Takeda, Exelixis, Ipsen and others.

For more detailed information, visit: https://www.delveinsight.com/report-store/cellular-mesenchymal-epithelial-transition-factor-mutated-non-small-cell-lung-cancer-market

#C MET mutated NSCLC market #c met mutated nsclc market share #c met mutated nsclc market size #c met mutated nsclc market trends #c met mutated nsclc epidemiology

0 notes

rohinic123-blog · 5 years ago

Text

Kinase Inhibitors Market - Major Factors Driving the Industry

Kinase Inhibitors Market: Introduction

Planning To Lay Down Future Strategy? Request Brochure Of Kinase Inhibitors Market

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=818

Increase in Incidence of Cancer, Rise in Awareness about Kinase Inhibitors, and Surge in Product Approvals to Drive Market

Non-receptor Tyrosine Kinase Inhibitors to Witness High Demand

To Obtain All-Inclusive Information On Forecast Analysis Of Kinase Inhibitors Market , Request A Discount

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=818

Oncology to be Key Application Area

Rise in Number of Hospital Pharmacies to Drive Market

North America to Dominate Global Market

Competition Landscape

More Trending Reports by Transparency Market Research –

Atherectomy Devices Market –

https://www.prnewswire.com/news-releases/atherectomy-devices-market-is-expected-to-earn-a-valuation-of-us735-million-by-2022-says-tmr-300794873.html

Hybrid Operating Room Market –

https://www.prnewswire.com/news-releases/hybrid-operating-room-market-to-attain-a-valuation-of-us828-1-billion-by-2022-inclusion-of-robot-assisted-surgeries-plays-crucial-role-in-expanding-the-market-says-tmr-300795719.html

0 notes

preefacto · 5 years ago

Text

Proliferative Vitreoretinopathy Market Strong Development and Huge Growth

With the rise in emphasis on prevention and treatment of proliferative vitreoretinopathy (PVR), a serious ailment that leads to blindness despite repeated treatment, the requirement for vitreoretinal centers has gained importance worldwide. Prevention of PVR development at early stage RRD for preserving visual function in patients has become a primary agenda among medical researchers and clinicians. A recent Fact.MR analysis envisages the proliferative vitreoretinopathy market to reflect a modest 4.0% CAGR during the forecast period (2018-2027).

Read Report Summary: https://www.factmr.com/report/795/proliferative-vitreoretinopathy-market However, establishment of vitreoretinal centers for the provision of advanced ophthalmological procedures is considered impractical, on account of increasing social security costs – a key challenge faced by nations across the globe. In contrast, remarkable advances have been made in medical equipment, and ultra-wide-field scanning laser ophthalmoscope (Optos) is one such advancement. This equipment facilitates the provision of wide-field, noninvasive, and nonmydriatic images, and is being increasingly employed for diagnosis and follow-up of PVR treatment evaluation. Advantages of deep learning in classifying Optus images in RRD have been observed to be slight, however the method has been deemed clinically imperative to achieve higher accuracy. It has been observed that multiple non-linear processing layers in deep learning approach can be leveraged for effective prevention and treatment of proliferative vitreoretinWith the rise in emphasis on prevention and treatment of proliferative vitreoretinopathy (PVR), a serious ailment that leads to blindness despite repeated treatment, the requirement for vitreoretinal centers has gained importance worldwide. Prevention of PVR development at early stage RRD for preserving visual function in patients has become a primary agenda among medical researchers and clinicians. A recent Fact.MR analysis envisages the proliferative vitreoretinopathy market to reflect a modest 4.0% CAGR during the forecast period (2018-2027). Hospital pharmacies are leading consumers in the pharmacy industry. Policymakers are becoming more aware about importance of offering effective pharmacy services coupled with safe and rational use of medications. In case of proliferative vitreoretinopathy, hospital pharmacies are considered to be radical asset of the modern pharmacy sector. They are vital part of hospitals and clinics, ensuring safe, effective, and economic use of drugs. According to the study, hospital pharmacies will continue to account for bulk shares of the market in the period of forecast.

To get Intensive Insights: https://www.factmr.com/connectus/sample?flag=RM&rep_id=795 Injectables will remain preferred over other mode of administrations of proliferative vitreoretinopathy management drugs. Treatment of PVR through intravitreal injectables has been considered beneficial as they delivery drugs directly to retina and vitreous. Simplicity of achieving intravitreal injection by doctors is a key factor driving adoption of this method. Subretinal injection has been gaining ground in the treatment of PVR, as it directly affects the resident cells & tissues in subretinal space. However, requirement for highly proficient and stable operators for subretinal injection continues to prevail as a major concern in the healthcare sector. Proliferative vitreoretinopathy, an inflammatory fibrotic disease, stems from inflammatory milieu post-RRD, which in turn prevents retinal healing. Several studies aimed at suppressing or preventing the development of PVR are being conducted worldwide, with some of the recent ones elucidating effect of “substance P (SP),” and targeted use of non-steroidal anti-inflammatory drugs such as “lornoxicam.” Research carried out on lornoxicam has not only demonstrated successful improvement in the condition of retina and choroid, but also reduced frequency of membrane formation significantly. Studies conducted on substance P have revealed that SP has the capability of inhibiting apoptosis, and epithelial-mesenchymal transition (EMT) induced by TNFα caused, thereby suppressing or preventing development of proliferative retinopathy.pathy by further studies.

Check out the Sample Report here: https://www.factmr.com/connectus/sample?flag=S&rep_id=795

About Us Fact.MR’s methodology is robust and comprehensive. We employ a range of tools and assets to develop an all-encompassing coverage of a range of industries. We compile data points at local, country, regional, and global level – our approach to capturing the finest nuances, without losing sight of the bigger picture helps us in developing accurate and reliable forecasts and estimates. Fact.MR has a standard set of guidelines and standards that help maintain a level of consistency across all of our research offerings. The standardization includes step-by-step documentation of the methodologies and guidelines on the sources that are to be used for incorporation of objective and accurate data. The standardization also involves use of industry-wide analytical tools, and rigorous quality checks to validate market forecasts and sizes. Our unwavering focus on standardization ensures that clients receive the same quality of research and analysis that Fact.MR is known for. Contact Us 11140 Rockville Pike Suite 400 Rockville, MD 20852 United States E: [email protected] Blog: https://theheraldmedia.com/

#Proliferative Vitreoretinopathy

0 notes

skylight20sworldblr-blog · 5 years ago

Text

10 Uplifting Stories To Get You Through The Week (1/20/19)

To enable you to finish the week on a constructive observe, we’ve got gathered into one record all of the information which may raise your spirits. That is the place you’ll discover a good mixture of feel-good tales mixed with vital achievements and tales of true togetherness. For those who want one thing bizarre and wacky, take a look at the offbeat record.

This week, we study that the world’s loneliest frog has discovered a girlfriend. A pet has a miraculous survival, and a person’s life is saved by beer. There are a couple of probably “game-changing” medical breakthroughs, an excessive feat of endurance, and a humbling act of forgiveness.

10 Courtroom Clemency

The sufferer of a DUI hit surprised the courtroom when she not solely forgave her attacker but in addition requested for his assist.

Three and a half years in the past, Montreal lady Tina Adams went out for a jog and was hit by 22-year-old Jordan Taylor, who was drunk behind the wheel. Nineteen surgical procedures later, Tina was capable of overcome the fractured backbone, cracked cranium, mind damage, and blood clots she suffered within the crash.

She might have survived, however Adams will cope with ache for the remainder of her life. She will not turn out to be a police officer due to her accidents and should not be capable of have youngsters. Within the years because the crash, Tina has traveled to colleges to speak about her expertise and to warn college students of the risks of drunk driving.

She stunned everybody when she requested Taylor to hitch her on these faculty talks throughout his sentencing listening to.[1] Tina believes that having the man who hit her there could have a huge effect on the scholars. She had considered doing this for some time however needed to attend till assembly him in courtroom to see if he confirmed real regret.

9 Romeo Finds His Juliet

A lonely male frog as soon as considered the final of his variety lastly has a associate after a decade of solitude.

Romeo is a Sehuencas water frog. Ten years in the past, conservationists realized that the species was in hassle in order that they collected him from the wild to put him right into a breeding program. Nevertheless, they couldn’t discover a feminine appropriate for him. Romeo was left in isolation in a Bolivian aquarium.

Now he’s not alone. A current expedition into the wilderness of Bolivia turned up 5 new Sehuencas water frogs—three males and two females. Certainly one of them, named Juliet, shall be positioned with Romeo within the hopes that they’ll breed collectively. In the intervening time, all the brand new amphibians are nonetheless in quarantine.

Herpetologists are hoping that opposites will appeal to when the 2 lastly meet. Their personalities appear to be antithetical to one another. Whereas Romeo is calm, sluggish, and doesn’t transfer round quite a bit, Juliet could be very lively, swims always, and eats every part in sight.[2]

eight The Chief And The Good Samaritan

Final Saturday, the Kansas Metropolis Chiefs scored a playoff victory over the Indianapolis Colts and made their solution to the AFC Championship Recreation later in the present day. Nevertheless, issues may need turned out in another way have been it not for a Good Samaritan who stopped to lend a serving to hand.

Hours earlier than the sport was set to start out at Arrowhead Stadium in Kansas Metropolis, Missouri, Chiefs offensive lineman Jeff Allen was caught within the snow. He in all probability would have missed the match if Dave Cochran hadn’t pulled over in his truck and helped Allen transfer his car.

Because it later turned out, Cochran was homeless and dwelling in his truck. Nevertheless, that didn’t cease him from aiding different individuals, which he thought-about his “natural habit.” When he pulled over, he didn’t know he was coping with a Kansas Metropolis Chiefs participant. He noticed somebody with Texas plates on his automotive and figured that he in all probability wasn’t used to driving in snowy circumstances.

Allen was eager to return the favor and took to Twitter the subsequent day to succeed in out to Cochran. Inside a couple of hours, he was capable of contact his snowy savior and provides him a few tickets to the AFC Championship Recreation. Cochran admitted that he was solely anticipating a “thank you” however that Allen’s gesture is “like a dream come true.”[3]

7 A New Remedy

In accordance with a brand new research revealed within the journal Most cancers Cell, Swiss researchers from the College of Basel are engaged on a revolutionary new remedy which may change breast most cancers cells into innocent fats cells.

Most cancers cells can bear a course of referred to as epithelial-mesenchymal transition (EMT). Usually, that is one thing that makes them extremely harmful because it permits them to unfold to different kinds of cells within the physique. Nevertheless, scientists consider that the identical mechanism can be utilized towards them.[4]

Throughout an experiment, researchers injected feminine mice with an aggressive type of feminine breast most cancers. When the cells began present process EMT, the scientists additionally injected an antidiabetic drug referred to as rosiglitazone and a most cancers inhibitor named trametinib.

The mixed remedy not solely turned the most cancers cells into fats cells but in addition stopped them from proliferating. Furthermore, lead writer Gerhard Christofori believes that the remedy may have a shorter, simpler path to human trials as a result of the medicine concerned are already permitted.

6 50,000 Cures For Loneliness

Together with his birthday approaching, World Struggle II navy veteran Duane Sherman was feeling a bit lonely. His daughter requested associates on Fb if they might ship him some well-wishes. He acquired over 50,000 letters.

In the meanwhile, there are birthday playing cards, thanks notes, small presents, and mementos filling postal bins stacked one on prime of one other all all through Sherman’s residence in Fullerton, California. And that solely represents a fraction of the whole. He needed to retailer hundreds of letters at a pal’s home, and lots of extra bins are nonetheless ready to be picked up on the submit workplace.[5]

He has acquired letters from all 50 states and 10 totally different nations. A number of the senders included the Pittsburgh Steelers and the Secretary of the Navy. The commander of the united statesCowpens even took the vet out to lunch whereas officers from the San Diego US Navy Sonar Faculty paid him a go to to take heed to his tales.

Sherman’s birthday was on December 30, and up to now, he has gone by means of fewer than 2,000 letters. He’s legally blind, so his daughter, Sue Morse, has to learn them to him. It’s fairly protected to say that they are going to be busy for the foreseeable future.

5 How To Get Over A Case Of The Mondays

Tomorrow is Blue Monday, thought-about to be probably the most depressing day of the yr. However is there any fact to this, and are there methods of getting via the day with a smile in your face?

Proper off the bat, should you reside within the southern hemisphere, you’re off the hook. The chilly climate is among the essential elements which contribute to the distress.

The idea of “Blue Monday” got here from UK psychologist Cliff Arnall in 2005. It often falls on the third Monday of the yr. Arnall claims to have developed an equation to find out the saddest day utilizing elements comparable to climate, debt degree, time handed because the holidays, and time handed since individuals broke their New Yr’s resolutions.[6]

The entire factor was truly devised for an advert marketing campaign for trip firm Sky Journey. It has been often dismissed as pseudoscience. Even Arnall admitted that he by no means meant to make the day sound unfavourable however to encourage individuals to take motion.

Let’s say you feel down within the dumps. Even when Blue Monday is a fantasy, seasonal affective dysfunction (SAD) is actual. If you wish to raise your spirits, psychologists advocate a little bit of train, a pleasant stroll outdoors, and enjoyable, difficult indoor actions.

A more healthy weight loss plan wealthy in good fat and antioxidants can even assist to stop melancholy. There’s even mild remedy utilizing particular SAD lamps to make up for all that daylight you’re lacking throughout winter.

four Pet Drop Has Joyful Ending

A tiny pet miraculously survived a drop from the sky with no critical accidents after being kidnapped by a hawk.

Final Saturday, development staff in Austin, Texas, responded to cries belonging to a Chihuahua pooch which weighed lower than zero.5 kilograms (1 lb). Questioning how the canine obtained there within the first place, they seemed up and noticed a hawk circling above. They realized that the raptor had picked up the pet and dropped it from the air.

The staff took the canine to the Austin Animal Middle the place vets have been stunned to find that the animal had solely delicate accidents and no damaged bones. The worst of the bunch have been the puncture wounds brought on by the hawk’s talons, however even these will heal up utterly in due time. The pet, now referred to as Tony Hawk, is resting together with his foster household and can discover a everlasting house in a couple of weeks.[7]

three A Recreation-Altering Transplant

Medical specialists are hailing a brand new process for liver transplants as a “game-changer” which can halve the ready listing.

Proper now, a few third of all donated livers by no means make it right into a affected person. On the similar time, 20 % of individuals in want of a brand new liver die on the ready record. That is because of the regular storage technique which makes use of ice. It causes the organ to deteriorate, and there’s solely a restricted time to transplant it earlier than it turns into unusable.

A brand new remedy makes use of normothermic perfusion machines to protect the liver. They continually pump the organ with oxygenated blood and vitamins at physique temperature in order that it may be saved for longer durations of time with no sick results.[8]

Furthermore, the blood remedy can truly be used to restore livers which have been broken throughout removing or have come from aged or sick donors. Subsequently, they permit docs to make use of organs which in any other case would have been discarded.

2 A Shattering Efficiency

New mom Jasmin Paris gained the Montane Backbone Race alongside the Pennine Approach within the UK, smashing the earlier document by over 12 hours.

The 431-kilometer (268 mi) race is likely one of the most grueling endurance challenges in Europe. Runners go from Derbyshire to the Scottish border, spending round two-thirds of their trek at the hours of darkness.

They cowl a variety of hilly terrain and should climb over 13,000 meters (43,000 ft) in complete. They’ve to hold their very own package and provides and may’t have a help workforce or runner be a part of them on the course. Rivals carry an emergency button in case they’re not capable of stroll.

With a time of 83 hours, 12 minutes, and 23 seconds, Paris turned the primary lady to win the race and had the quickest time ever—by far. The earlier document of 95 hours and 17 minutes was set in 2016 by Eoin Keith.

Just some checkpoints are allowed in the course of the race, and Paris slept for less than three hours throughout the entire thing. She admitted that she had begun hallucinating by the final day. She noticed animals seem out of nowhere and timber doing morning stretches.[9]

1 Beer Saves Life

Beer might be good for you, and 48-year-old Vietnamese man Nguyen Van Nhat is proof of that. When he got here into the hospital unconscious, affected by methanol poisoning, docs pumped him with 15 cans of beer and saved his life.

Methanol is a type of alcohol. However it’s a very poisonous one which is usually present in paints, thinners, cleansing merchandise, and antifreeze slightly than drinks. Business spirit producers take additional steps to take away methanol from their merchandise, though it could possibly nonetheless be present in harmful portions in bootleg liquor.

The supply of the methanol consumed by Nguyen Van Nhat is unknown, however he had over 1,000 occasions the really helpful restrict. Docs knew that he would die if his liver processed all of the methanol in his system. The liver converts the alcohol into formaldehyde which is then damaged down into formic acid. Docs have been in search of a method to decelerate the method, they usually discovered it with beer.

Beer accommodates one other sort of alcohol referred to as ethanol. It’s the alcohol present in most shopper drinks on the planet. Though it’s nonetheless poisonous, its results are far milder. Because it occurs, the liver first processes ethanol and solely afterward strikes as much as methanol.

Subsequently, so long as there was beer in Nguyen Van Nhat’s system, his physique wouldn’t be broken by the methanol. Docs transfused 15 cans value of beer into the affected person at a fee of a can per hour, thus giving the dialysis sufficient time to take away the methanol from his system.[10]

The post 10 Uplifting Stories To Get You Through The Week (1/20/19) appeared first on List Technology.

#Our World #Technology

0 notes

aethermystfan-blog · 5 years ago

Text

10 Uplifting Stories To Get You Through The Week (1/20/19)

10 Courtroom Clemency

The sufferer of a DUI hit surprised the courtroom when she not solely forgave her attacker but in addition requested for his assist.

9 Romeo Finds His Juliet

A lonely male frog as soon as considered the final of his variety lastly has a associate after a decade of solitude.

eight The Chief And The Good Samaritan

7 A New Remedy

6 50,000 Cures For Loneliness

5 How To Get Over A Case Of The Mondays

Tomorrow is Blue Monday, thought-about to be probably the most depressing day of the yr. However is there any fact to this, and are there methods of getting via the day with a smile in your face?

Proper off the bat, should you reside within the southern hemisphere, you’re off the hook. The chilly climate is among the essential elements which contribute to the distress.

four Pet Drop Has Joyful Ending

A tiny pet miraculously survived a drop from the sky with no critical accidents after being kidnapped by a hawk.

three A Recreation-Altering Transplant

Medical specialists are hailing a brand new process for liver transplants as a “game-changer” which can halve the ready listing.

2 A Shattering Efficiency

New mom Jasmin Paris gained the Montane Backbone Race alongside the Pennine Approach within the UK, smashing the earlier document by over 12 hours.

1 Beer Saves Life

The post 10 Uplifting Stories To Get You Through The Week (1/20/19) appeared first on List Technology.

#Our World #Technology

0 notes

jimeshbathija3896-blog · 5 years ago

Text

10 Uplifting Stories To Get You Through The Week (1/20/19)

10 Courtroom Clemency

The sufferer of a DUI hit surprised the courtroom when she not solely forgave her attacker but in addition requested for his assist.

9 Romeo Finds His Juliet

A lonely male frog as soon as considered the final of his variety lastly has a associate after a decade of solitude.

eight The Chief And The Good Samaritan

7 A New Remedy

6 50,000 Cures For Loneliness

5 How To Get Over A Case Of The Mondays

Tomorrow is Blue Monday, thought-about to be probably the most depressing day of the yr. However is there any fact to this, and are there methods of getting via the day with a smile in your face?

Proper off the bat, should you reside within the southern hemisphere, you’re off the hook. The chilly climate is among the essential elements which contribute to the distress.

four Pet Drop Has Joyful Ending

A tiny pet miraculously survived a drop from the sky with no critical accidents after being kidnapped by a hawk.

three A Recreation-Altering Transplant

Medical specialists are hailing a brand new process for liver transplants as a “game-changer” which can halve the ready listing.

2 A Shattering Efficiency

New mom Jasmin Paris gained the Montane Backbone Race alongside the Pennine Approach within the UK, smashing the earlier document by over 12 hours.

1 Beer Saves Life

The post 10 Uplifting Stories To Get You Through The Week (1/20/19) appeared first on List Technology.

#Our World #Technology

0 notes

superplhis-blog · 5 years ago

Text

10 Uplifting Stories To Get You Through The Week (1/20/19)

10 Courtroom Clemency

The sufferer of a DUI hit surprised the courtroom when she not solely forgave her attacker but in addition requested for his assist.

9 Romeo Finds His Juliet

A lonely male frog as soon as considered the final of his variety lastly has a associate after a decade of solitude.

eight The Chief And The Good Samaritan

7 A New Remedy

6 50,000 Cures For Loneliness

5 How To Get Over A Case Of The Mondays

Tomorrow is Blue Monday, thought-about to be probably the most depressing day of the yr. However is there any fact to this, and are there methods of getting via the day with a smile in your face?

Proper off the bat, should you reside within the southern hemisphere, you’re off the hook. The chilly climate is among the essential elements which contribute to the distress.

four Pet Drop Has Joyful Ending

A tiny pet miraculously survived a drop from the sky with no critical accidents after being kidnapped by a hawk.

three A Recreation-Altering Transplant

Medical specialists are hailing a brand new process for liver transplants as a “game-changer” which can halve the ready listing.

2 A Shattering Efficiency

New mom Jasmin Paris gained the Montane Backbone Race alongside the Pennine Approach within the UK, smashing the earlier document by over 12 hours.

1 Beer Saves Life

The post 10 Uplifting Stories To Get You Through The Week (1/20/19) appeared first on List Technology.

#Our World #Technology

0 notes

apurvafmi-blog · 6 years ago

Link

Circulating tumor cells are tumor cells that have shed from primary tumor and circulated to the different part of the body through lymphatic system and blood circulation system. Circulating tumor cells are useful for the detection of the cancer and to understand the disease progression and projection of treatment required for tumor elimination. Moreover various tumor markers can also be used with circulating tumor cells for the diagnosis of the cancer.

Circulating tumor cell testing enables the detection and quantification of tumor cells in the blood of cancer patients. With the biomarker analysis, the circulating tumor cells testing helps in the characterization of tumor cells. Circulating tumor cells tests have application in investigation of various types of cancer such as breast cancer, prostate cancer and colon cancer.

The growing prevalence of cancer is one of the major reasons behind the growth of circulating tumor cell testing market. According to NIH, National Cancer Institute, cancer is one of the major reasons of death globally. In 2012, there were around 8.2 Mn cancer related death and 14.1 Mn new cases of cancer globally. By 2030 the number of new cases of cancer is expected to reach to more than 23 Mn.

As per the Global Cancer Observatory (GCO), colorectal cancer (CRC) is the third most common in men and second most common cancer in women worldwide. According to an estimation from the National Cancer Institute, in 2018 colorectal cancer is projected to contribute around 8.1% of all new cancer cases with estimated deaths around 50,630, which is 8.3% of all cancer deaths caused in the U.S.As reported by the Cancer Research UK, there were 41,804 new cases of colorectal cancer in 2015 and 16,384 deaths due to colon cancer in the U.K.

Request Sample Report@ https://www.persistencemarketresearch.com/samples/25504

Circulating tumor cells can also be used for liquid biopsy. Circulating tumor cells are the subset of cancer cells in the bloodstream. The increasing demand for high Benefit-Cost Ratio (BCR) associated with circulating tumor cell testing is also a major factor which can fuel the growth of circulating tumor cell testing market. Recent technological advances have enabled the isolation of circulating tumor cells from the blood of cancer patient. The circulating tumor cell testing is useful in monitoring the active disease and also an alternative for traditional invasive biopsy technique.

Increase in genetic disorder, alcohol consumption, smoking and lifestyle changes are the major factor behind the rise in cancer cases and also contributing factor for the growth of the circulating tumor cell market.

The circulating tumor cell testing is also a useful tool for the development of preventive medicine for cancer. Circulating tumor cell testing can help understand and asses the mechanism of drug during in-vitro experiment in preclinical studies.

The development of Cluster Chip Technology is another reason to grow the market for circulating tumor cell testing market. Circulating tumor cells are living tumor cells which are found in the bloodstream of cancer patient at extremely low levels – about one in a billion cells. Cluster chip technology can be used for the isolation of circulating tumor cells from blood stream using a microfluidic device.

The characterization and detection of circulating tumor cells are difficult due the extremely rare presence of circulating tumor cells in blood stream. So it’s become a stringent process to isolate the circulating tumor cells which ultimately increase the cost of detection process. Moreover due to the diversified nature and short lived nature of circulating tumor cells and shortage of specific biomarker can restrain the growth of circulating tumor cell testing market.

To gain a comprehensive and better understanding of the future market equity, the circulating tumor cell testing market is segmented based on type of technology, application and region.

Based on the type of technology, the circulating tumor cell testing market is segmented into:

Circulating Tumor Cell Enrichment Methods

Circulating Tumor Cell Detection Methods

Single Spiral Micro Channel technology for circulating tumor cell testing

Microchips technology circulating tumor cell testing

Negative Selection for circulating tumor cell testing

In-Vivo Positive Selection for circulating tumor cell testing

Ex-Vivo Positive Selection for circulating tumor cell testing

Others technology for circulating tumor cell testing

Immunocytochemical Technology for circulating tumor cell testing

Molecular (RNA) based Technology for circulating tumor cell testing

Xenotransplantation Technology for circulating tumor cell testing

Others

Based on the application, the circulating tumor cell testing market is segmented into:

Circulating tumor cell testing for Epithelial-mesenchymal Transition (EMT) Biomarkers Development

Circulating tumor cell testing for Tumorigenesis Research

Circulating tumor cell testing for Cancer Stem Cell

Others

Request Report TOC@ https://www.persistencemarketresearch.com/methodology/25504

The U.S. circulating tumor cell testing market is projected to witness significant growth in the North America market, owing to the increased awareness and growing geriatric population. Asia Pacific, mainly China, India, and other Southeast Asian regions, and Europe are expected to remain lucrative markets for circulating tumor cell testing during the forecast period because of the growing demand for healthcare services. The MEA circulating tumor cell testing market is expected to witness moderate growth, due to poor healthcare infrastructure, resulting in less availability of healthcare procedures, and less per capita income resulting in less affordability.

Examples of some of the key participants in the circulating tumor cell testing market identified across the value chain include Advanced Cell Diagnostics, Inc., Aviva Biosciences., Cynvenio Biosystems, Inc., ApoCell., Biocept Inc., Qiagen., Miltenyi Biotec., Clearbridge Biomedics Pte Ltd., and Menarini Silicon Biosystems.

#Circulating Tumor Cell Testing Market

0 notes

cancersfakianakis1 · 6 years ago

Text

Cancers, Vol. 10, Pages 346: The “Yin and Yang” of Natural Compounds in Anticancer Therapy of Triple-Negative Breast Cancers

Cancers doi: 10.3390/cancers10100346

Authors: Elizabeth Varghese Samson Mathews Samuel Mariam Abotaleb Sohaila Cheema Ravinder Mamtani Dietrich Büsselberg

Among the different types of breast cancers, triple-negative breast cancers (TNBCs) are highly aggressive, do not respond to conventional hormonal/human epidermal growth factor receptor 2 (HER2)-targeted interventions due to the lack of the respective receptor targets, have chances of early recurrence, metastasize, tend to be more invasive in nature, and develop drug resistance. The global burden of TNBCs is increasing regardless of the number of cytotoxic drugs being introduced into the market each year as they have only moderate efficacy and/or unforeseen side effects. Therefore, the demand for more efficient therapeutic interventions, with reduced side effects, for the treatment of TNBCs is rising. While some plant metabolites/derivatives actually induce the risk of cancers, many plant-derived active principles have gained attention as efficient anticancer agents against TNBCs, with fewer adverse side effects. Here we discuss the possible oncogenic molecular pathways in TNBCs and how the purified plant-derived natural compounds specifically target and modulate the genes and/or proteins involved in these aberrant pathways to exhibit their anticancer potential. We have linked the anticancer potential of plant-derived natural compounds (luteolin, chalcones, piperine, deguelin, quercetin, rutin, fisetin, curcumin, resveratrol, and others) to their ability to target multiple dysregulated signaling pathways (such as the Wnt/β-catenin, Notch, NF-κB, PI3K/Akt/mammalian target of rapamycin (mTOR), mitogen-activated protein kinase (MAPK) and Hedgehog) leading to suppression of cell growth, proliferation, migration, inflammation, angiogenesis, epithelial-mesenchymal transition (EMT) and metastasis, and activation of apoptosis in TNBCs. Plant-derived compounds in combination with classical chemotherapeutic agents were more efficient in the treatment of TNBCs, possibly with lesser side effects.

https://ift.tt/2MRzzJs

#Oncology-Sfakianakis

0 notes

marketworld-blog1 · 7 years ago

Text

Kinase Inhibitors Market Key Region, Production and Growth Prospect Forecast Till 2022

In pharmaceutical sector, anti – cancer drugs form the most lucrative segment. From the past market trend it has shown that this anti – cancer drugs or kinase inhibitors has accounted over 10% of the global market. In the forecasted year of 2015 to 2022, Kinase Inhibitors Market CAGR is expected to witness a double digit growth. The factors identified which are driving the growth of the Kinase Inhibitors market are incidental rise of different types of cancer patients, rise in the aging population and increase in the focus to launch innovative medicines by the pharmaceutical companies. These key factors combined with competition from several pharmaceutical and oncology associations to paunch new product is propelling the growth of the market exponentially.

Kinase inhibitors are basically a type of enzyme of protein base. Use of Kinase enzyme helps to shuffle the protein structure by the transfer of phosphates. These phosphates get collected from ATP. ATP is Adenosine Triphosphate. Kinase on protein bases has several functions. These functions includes regulating variety of cell cycles and their phases, cell differentiation, cell proliferation, and apoptosis. These functions helps to regulate various activities of cancerous cell.

Browse Details of Kinase Inhibitors Market at: https://www.millioninsights.com/industry-reports/kinase-inhibitors-market

Kinase inhibitors are now considered to be the novel therapeutics. This is because these inhibitors are targeted to improve the patients survival rate by several preventive measures which will hinder the growth of tumors selectively as opposed to the classical chemo therapy which indiscriminate the cell death. Reports from American cancer association say that in the year 2014, the global sales for small molecule kinase inhibitors generated USD 18.49 billion of revenues for manufactures. This trend is expected to see a phenomenal growth till the forecast period of 2022.

The sales growth is expected to exceed the wider cancer treating drug market in the upcoming years. This is because of huge expansion of kinase inhibitors in terms of clinical usage among stratified patient as an end user. Growth of this market is expected to improve by launch and uptake of the advanced version of breakthrough therapies such as a marketed product, imbruvica (Ibrutinib), candidate drugs pablociclib, Idelalisib and ABT – 199.Market trend also quotes that there will more incidental rise of cancerous patients in the upcoming years. These is validated mostly the global associations related to oncology treatment. So the manufactures for kinase inhibitors have a potential opportunity in the near future.

This is mainly because the kinase inhibitors are are being considered as a key medication to prevent proliferation of cancerous cells. Most of the drugs which are going to be used to oncology treatment in clinical trials phase are expected to be launched in the next five to six years based on the strength of kinase activities of these drugs. However it has also been identified that healthcare cost containment issues and cost cutting in research funding are the major restraints for the growth of this market. For example, the cost of Tyrosin Kinase Inhibitors (TKI) was approximated to be USD 26400 in non-pharmaceutical spending in the year 2012 as per American Cancer Society.

The global market for Kinase Inhibitors are segmented on the basis of types, by geography and by target end users. The target end users for this market are mainly pharmaceutical companies, private and government research institutes, healthcare institutes and academic institutes. By types the global market is further segmented into Tyrosine Kinase Inhibitors (TKI), Receptor Tyrosine Kinase Inhibitors which includes EGFR, PDGFR, VEGFR,HER2 which is a type of Non Receptor Tyrosine Kinase Inhibitor (RCTKI), BCR – ABL, Janus Kinase Inhibitor (JAK), Mesenchymal Epithelial Transition Growth Factor (c – MET), Speen Tyrosine Kinase (SYK) Inhibitors which is again further divided into classes such as Mulikinase Inhibitors, Threonine Kinase Inhibitors, m TOR Kinase Inhibitors, B RAFM, RHO Kinase Inhibitors, Cyclin Dependent Kinase Inhibitors, Aurora Kinase Inhibitors, MAP or MEK Kinase Inhibitors, JNK Inhibitors, Protein Kinase c Inhibitors, PI3K Inhibitors, others ( Monoclonal Antibody Kinase Inhibitors) which is again classified into Humanized Monoclonal Antibody, Chimeric Monoclonal Antibody, Humanized Monoclonal Antibody.

Request Free Sample Copy of Kinase Inhibitors Market at: https://www.millioninsights.com/industry-reports/kinase-inhibitors-market/request-sample

By geography the global market is segmented into major regions which include North America, Europe, Asia Pacific and rest of the world (R o W). As with other medicines for cancer the dominant countries for the growth of Kinase Inhibitor market are Japan, the European Union countries and the United States. These countries generate the highest revenue the Kinase Inhibitor market. However over the next five to six years this market is expected to see an exponential growth from BRIC countries. This is because of increase in the number of health insurances, healthcare reforms, and increase in the affluence segment from this region.

In the forecasted period of 2015 to 2022 the first generation of Kinase Inhibitor drug is also expected to lose intellectual property which includes patents and trademarks protection and competition from low cost generic substitutes. This will temporarily restricted the expected expansion in many lucrative submarkets. The key players in Kinase inhibitors market are Bristol Meyers Squibb, Boehringer Ingelhgeim, Cytrx Corporation, Eisai Inc., Eton Bioscience Inc., Novartis International Ag, Glaxosmithkline, Merk Serona Sa, Osi Pharmaceuticals Llc., Pfizer. These major leaders face a stiff competition to retain their sustainable foothold in this market measured on different competitive market dynamics. For example Novartis’s Gleevec for leukemia treatment is amongst the bestselling Kinase Inhibitors.

#Kinase Inhibitors Market Trend Kinase Inhibitors Market Growth Kinase Inhibitors Market Research Report Kinase Inhibitors Market Share Kinas

0 notes